What to Check When Your GLP-3/RT Arrives
Not every irregularity on arrival is a defect, and not every compound is defective under the same conditions. Here is what actually matters when a GLP-3/RT shipment arrives.
Overview
The dry powder travels well, so a warm journey is generally fine. What is not fine is a vial arriving with the contents already liquefied or partly dissolved — that means moisture reached it, and it should be rejected.
What GLP-3/RT actually is
GLP-3/RT is an engineered molecule built to act on three receptors at once, all belonging to the system of hormones your gut releases around eating. Getting one chain to fit three different targets well is a genuinely hard design problem, which is why molecules like this appeared years after simpler ones.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
Arrival inspection for GLP-3/RT
Inspect for cake integrity. GLP-3/RT is a long, expensive synthesis and the dry material is robust, so ambient transit is generally acceptable — but any vial arriving with the cake already dissolved or partially liquefied has seen moisture and should be rejected.
Storage on arrival
Documentation to check
Confirm the mass near 4759.5 Da. For lipidated peptides the most valuable extra data point is aggregate content by size-exclusion chromatography — RP-HPLC purity can read high while soluble aggregates are present, because aggregates often dissociate under the organic mobile phase.
What GLP-3/RT is studied for
The defining feature: simultaneous GIP, GLP-1, and glucagon receptor activity from one chain.
Glucagon-receptor activity is studied for its contribution to energy expenditure, distinguishing triagonists from dual agonists.
Investigated in metabolic research models for effects on glucose homeostasis.
A major focus of the preclinical literature on this compound class.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist GLP-3/RT for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
- Browse current GLP-3/RT literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More GLP-3/RT reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
Compound-specific bench practices, and the errors most often made with this molecule.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Shipping & Receiving reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
GLP-3/RT is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.